Form 4: Edesa Biotech CEO Pardeep Nijhawan Boosts Stake with Significant RSU Grants

Edesa Biotech's CEO, Pardeep Nijhawan, has reported the acquisition of 270,844 restricted share units through recent grants, significantly increasing his direct and indirect beneficial ownership in the company.

Summary

• Pardeep Nijhawan, who serves as Chief Executive Officer, Director, and a 10% Owner of Edesa Biotech, Inc. (EDSA), has reported changes in his beneficial ownership.
• On May 29, 2025, Mr. Nijhawan was granted 263,200 restricted share units (RSUs) under the Issuer's 2019 Equity Incentive Compensation Plan.
• Of these RSUs, 166,287 shares are scheduled to vest monthly in equal proportions over twelve (12) months, commencing on the grant date.
• The remaining 96,913 shares from the May 29th grant are set to vest in equal proportions over thirty-six (36) months, also commencing on the grant date.
• An additional grant of 7,644 restricted share units occurred on June 2, 2025, which vested in full upon grant, also pursuant to the 2019 Equity Incentive Compensation Plan.
• Following these transactions, Mr. Nijhawan's direct beneficial ownership of common shares stands at 449,767.
• His indirect beneficial ownership includes 341,702 common shares held by Pardeep Nijhawan Medicine Professional Corporation, 32,609 shares by The New Nijhawan Family Trust 2015, 32,013 shares by The Digestive Health Clinic Inc., and 53,104 shares by 1968160 Ontario Inc.
• The total beneficial ownership, encompassing both direct and indirect holdings, amounts to 909,195 common shares.
• All reported transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of restricted share units to the CEO, a significant insider, generally signals management's confidence in the company's future and aligns their interests with shareholders. This is a positive indicator for investor confidence, although it is a routine compensation event rather than a performance announcement.

Positives

• The CEO's increased beneficial ownership through significant RSU grants aligns his interests with those of shareholders, indicating strong confidence in the company's long-term prospects.
• The grants are part of the company's established 2019 Equity Incentive Compensation Plan, suggesting a structured and performance-oriented approach to executive compensation and retention.
• A portion of the RSUs (7,644 shares) vested immediately upon grant, providing immediate equity to the CEO.

Future Outlook

The vesting schedules for the granted restricted share units indicate a future commitment of the CEO to the company, with shares vesting over 12 and 36 months, aligning his long-term interests with shareholder value. No explicit forward-looking statements regarding company performance or financial guidance are provided in this filing.

Management Comments

• The filing was signed by Peter J. Weiler, Attorney-in-Fact for Pardeep Nijhawan.

Industry Context

This Form 4 filing details an insider transaction, which is a routine disclosure for public company executives and directors. While it doesn't directly reflect broader industry trends, the use of equity incentive plans and RSU grants is a common practice across the biotech sector and other industries to attract, retain, and incentivize key talent by aligning their financial interests with the company's performance.

Corporate Governance

Related Party Transactions

• Pardeep Nijhawan Medicine Professional Corporation, The Digestive Health Clinic Inc., and 1968160 Ontario Inc. are wholly-owned by the Reporting Person, and hold 341,702, 32,013, and 53,104 common shares respectively.
• The New Nijhawan Family Trust 2015, where the Reporting Person is a co-trustee, holds 32,609 common shares.

Stakeholder Impact

• **Shareholders**: The increased beneficial ownership by the CEO, particularly through long-term vesting equity, aligns management's incentives with shareholder value creation, potentially boosting investor confidence and signaling a commitment to the company's future.
• **Employees**: The use of an equity incentive plan suggests a framework for performance-based compensation that could extend to other key employees, fostering a culture of shared success and retention within the company.

Next Steps

• Vesting of 166,287 restricted share units monthly over 12 months, commencing May 29, 2025.
• Vesting of 96,913 restricted share units over 36 months, commencing May 29, 2025.

Key Dates

Recommendation

Keywords

Edesa Biotech, EDSA, Pardeep Nijhawan, SEC Form 4, Insider Trading, Beneficial Ownership, Restricted Share Units, RSU Grant, Equity Incentive Plan, Executive Compensation, Biotech, Director, CEO, 10b5-1 Plan